Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21


Human pollution exposure correlates with accelerated ultrastructural degradation of hair fibers.

Naudin G, Bastien P, Mezzache S, Trehu E, Bourokba N, Appenzeller BMR, Soeur J, Bornschlögl T.

Proc Natl Acad Sci U S A. 2019 Sep 10;116(37):18410-18415. doi: 10.1073/pnas.1904082116. Epub 2019 Aug 26.


Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy.

van den Blink B, Dillingh MR, Ginns LC, Morrison LD, Moerland M, Wijsenbeek M, Trehu EG, Bartholmai BJ, Burggraaf J.

Eur Respir J. 2016 Mar;47(3):889-97. doi: 10.1183/13993003.00850-2015. Epub 2016 Feb 11.


Hillmen trial of alemtuzumab in first-line chronic lymphocytic leukemia still provides valuable information.

Sirard C, Trehu EG.

J Clin Oncol. 2008 May 10;26(14):2411-2; author reply 2412-3. doi: 10.1200/JCO.2008.16.3782. No abstract available.


Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.

Attar EC, De Angelo DJ, Supko JG, D'Amato F, Zahrieh D, Sirulnik A, Wadleigh M, Ballen KK, McAfee S, Miller KB, Levine J, Galinsky I, Trehu EG, Schenkein D, Neuberg D, Stone RM, Amrein PC.

Clin Cancer Res. 2008 Mar 1;14(5):1446-54. doi: 10.1158/1078-0432.CCR-07-4626.


Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.

Strauss SJ, Maharaj L, Hoare S, Johnson PW, Radford JA, Vinnecombe S, Millard L, Rohatiner A, Boral A, Trehu E, Schenkein D, Balkwill F, Joel SP, Lister TA.

J Clin Oncol. 2006 May 1;24(13):2105-12. Epub 2006 Apr 10.


Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.

Berenson JR, Jagannath S, Barlogie B, Siegel DT, Alexanian R, Richardson PG, Irwin D, Alsina M, Rajkumar SV, Srkalovic G, Singhal S, Limentani S, Niesvizky R, Esseltine DL, Trehu E, Schenkein DP, Anderson K.

Cancer. 2005 Nov 15;104(10):2141-8.


Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.

Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T, Johri AR, Jones PE, Ivanova A, Van Deventer HW, Gabriel DA, Shea TC, Mitchell BS, Adams J, Esseltine DL, Trehu EG, Green M, Lehman MJ, Natoli S, Collins JM, Lindley CM, Dees EC.

Blood. 2005 Apr 15;105(8):3058-65. Epub 2004 Dec 30.


Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, Dumetrescu O, Esseltine D, Trehu E, Adams J, Schenkein D, Zelenetz AD.

J Clin Oncol. 2005 Feb 1;23(4):676-84. Epub 2004 Dec 21.


Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM.

J Clin Oncol. 2005 Feb 1;23(4):667-75. Epub 2004 Dec 21.


Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II.

O'Connor O, Wright J, Moskowitz CH, Muzzy J, MacGregor-Cortelli B, Hamlin P, Straus D, Trehu E, Schenkein DP, Zelenetz AD.

J Natl Compr Canc Netw. 2004 Nov;2 Suppl 4:S21-2.


A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor.

McDermott DF, Trehu EG, Mier JW, Sorce D, Rand W, Ronayne L, Kappler K, Clancy M, Klempner M, Atkins MB.

Clin Cancer Res. 1998 May;4(5):1203-13.


Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma.

Du Bois JS, Trehu EG, Mier JW, Shapiro L, Epstein M, Klempner M, Dinarello C, Kappler K, Ronayne L, Rand W, Atkins MB.

J Clin Oncol. 1997 Mar;15(3):1052-62.


Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera.

Trehu EG, Mier JW, Dubois JS, Sorce D, Klempner MS, Epstein M, Dinarello CA, Shapiro L, Kappler K, Ronayne L, Atkins MB.

Clin Cancer Res. 1996 Aug;2(8):1341-51.


A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinoma.

Weiss GR, Margolin KA, Sznol M, Atkins MB, Oleksowicz L, Isaacs R, Sosman JA, Doroshow JH, Trehu EG, Dutcher JP, et al.

J Immunother Emphasis Tumor Immunol. 1995 Jul;18(1):52-6. No abstract available.


Induction of circulating antagonists to IL-1 and TNF by IL-2 administration and their effects on IL-2 induced cytokine production in vitro.

Tilg H, Shapiro L, Vannier E, Poutsiaka DD, Trehu E, Atkins MB, Dinarello CA, Mier JW.

J Immunol. 1994 Mar 15;152(6):3189-98.


Induction of circulating soluble tumour necrosis factor receptor and interleukin 1 receptor antagonist following interleukin 1 alpha infusion in humans.

Tilg H, Trehu E, Shapiro L, Pape D, Atkins MB, Dinarello CA, Mier JW.

Cytokine. 1994 Mar;6(2):215-9.


Possible myocardial toxicity associated with interleukin-4 therapy.

Trehu EG, Isner JM, Mier JW, Karp DD, Atkins MB.

J Immunother Emphasis Tumor Immunol. 1993 Nov;14(4):348-51.


A method for the detection of erythrocyte-bound interleukin-8 in humans during interleukin-1 immunotherapy.

Tilg H, Pape D, Trehu E, Shapiro L, Atkins MB, Dinarello CA, Mier JW.

J Immunol Methods. 1993 Aug 9;163(2):253-8.


Suppression of IL-2-induced SAA gene expression in mice by the administration of an IL-1 receptor antagonist.

Numerof RP, Sipe JD, Trehu EG, Dinarello CA, Mier JW.

Cytokine. 1992 Nov;4(6):555-60.


Supplemental Content

Support Center